[PCSK9 inhibitors: how to bridge the gap between scientific evidence and regulatory barriers?]

G Ital Cardiol (Rome). 2018 Feb;19(2):77-80. doi: 10.1714/2868.28938.
[Article in Italian]
No abstract available

MeSH terms

  • Anticholesteremic Agents / pharmacology*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Drug and Narcotic Control
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy*
  • Humans
  • PCSK9 Inhibitors*

Substances

  • Anticholesteremic Agents
  • PCSK9 Inhibitors
  • PCSK9 protein, human